Halozyme Therapeutics Cash Flow Statement
NASDAQ: HALOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Halozyme Therapeutics free cash flow
In fiscal 2025, Halozyme Therapeutics generated $651.6 million of operating cash flow and spent $7.0 million on capital expenditures. That left free cash flow of $644.6 million, a free-cash-flow margin of 46.2% of revenue. Free cash flow was up 37.6% from the prior year's $468.4 million.
Halozyme Therapeutics returned $342.4 million to shareholders through share repurchases, equal to 53% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Halozyme Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 316.89M | 444.09M | 281.59M | 202.13M | 402.71M | 129.09M | -72.24M | -80.33M | 62.97M | -103.02M |
| Net Income growth (YoY) | -28.64% | +57.71% | +39.31% | -49.81% | +211.97% | — | — | -227.57% | — | — |
| Depreciation & Amortization | 11.39M | 10.26M | 11.08M | 6.49M | 3.00M | 3.28M | 4.07M | 2.39M | 2.16M | 2.41M |
| Stock-Based Compensation | 51.56M | 43.38M | 36.62M | 24.40M | 20.82M | 17.20M | 34.78M | 35.70M | 30.67M | 25.59M |
| Change in Working Capital | -152.26M | -89.28M | -38.67M | -88.44M | 3.74M | -103.73M | -50.54M | -2.87M | 43.45M | 17.68M |
| Operating Cash Flow | 651.56M | 479.06M | 388.57M | 240.11M | 299.44M | 55.45M | -85.42M | -49.50M | 134.05M | -50.38M |
| Capital Expenditures | -6.97M | -10.70M | -15.29M | -4.81M | -1.46M | -2.50M | -4.04M | -4.66M | -1.35M | -3.14M |
| Investing Cash Flow | -545.81M | -262.72M | -96.91M | -487.00M | -406.29M | 78.35M | -5.55M | 2.49M | -163.73M | -76.77M |
| Share Repurchases | -342.37M | -250.00M | -402.38M | -200.00M | -350.06M | -150.12M | -200.00M | 0 | 0 | — |
| Debt Issued | — | — | 0 | 0 | 784.88M | 0 | 447.35M | 0 | 0 | 203.01M |
| Financing Cash Flow | -85.17M | -218.86M | -407.99M | 362.37M | 77.86M | -106.28M | 153.22M | -63.80M | 131.66M | 150.62M |
| Net Change in Cash | 20.57M | -2.52M | -116.33M | 115.48M | -28.98M | 27.52M | 62.24M | -110.80M | 101.98M | 23.47M |
| Free Cash Flow | 644.59M | 468.37M | 373.28M | 235.30M | 297.98M | 52.95M | -89.46M | -54.16M | 132.70M | -53.52M |
This table shows 10 annual periods of Halozyme Therapeutics's cash flow statement, from FY 2025 back to FY 2016, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow HALO's reporting calendar. What is a cash flow statement?